149 related articles for article (PubMed ID: 37929602)
21. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
22. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy.
Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
[TBL] [Abstract][Full Text] [Related]
24. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome.
Liu HH; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Dong Q; Qian J; Dou KF; Li JJ
J Transl Med; 2022 May; 20(1):243. PubMed ID: 35619146
[TBL] [Abstract][Full Text] [Related]
27. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
28. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
Goldberg AC; Banach M; Catapano AL; Duell PB; Leiter LA; Hanselman JC; Lei L; Mancini GBJ
Atherosclerosis; 2023 Nov; 384():117192. PubMed ID: 37648637
[TBL] [Abstract][Full Text] [Related]
30. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
[TBL] [Abstract][Full Text] [Related]
31. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
Ridker PM; Tuttle KR; Perkovic V; Libby P; MacFadyen JG
Eur Heart J; 2022 Dec; 43(46):4832-4844. PubMed ID: 35943897
[TBL] [Abstract][Full Text] [Related]
32. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
[TBL] [Abstract][Full Text] [Related]
33. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
34. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
Furtado RHM; Fagundes AA; Oyama K; Zelniker TA; Tang M; Kuder JF; Murphy SA; Hamer A; Wang H; Keech AC; Giugliano RP; Sabatine MS; Bergmark BA
Circ Cardiovasc Interv; 2022 Mar; 15(3):e011382. PubMed ID: 35209731
[TBL] [Abstract][Full Text] [Related]
35. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP
JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials.
Zhao X; Ma X; Luo X; Shi Z; Deng Z; Jin Y; Xiao Z; Tan L; Liu P; Jiang S; Shu Y; Tang B; Qiu C
BMC Pharmacol Toxicol; 2020 Dec; 21(1):86. PubMed ID: 33276805
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: A pilot systematic review and meta-analysis of randomized controlled trials.
Goyal A; Changez MIK; Tariq MD; Mushtaq F; Shamim U; Sohail AH; Mahalwar G
Curr Probl Cardiol; 2024 Feb; 49(2):102236. PubMed ID: 38043880
[TBL] [Abstract][Full Text] [Related]
40. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; MacFadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
N Engl J Med; 2008 Nov; 359(21):2195-207. PubMed ID: 18997196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
